A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD

BACKGROUND: Many patients with chronic obstructive pulmonary disease (COPD) still experience daily symptoms, exacerbations, and accelerated lung function decline, even when receiving maximal combined treatment with inhaled long-acting bronchodilators and corticosteroids. Novel treatment options are...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Dave, Martinez, Fernando J., Watz, Henrik, Bengtsson, Thomas, Maurer, Brian T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011474/
https://www.ncbi.nlm.nih.gov/pubmed/32041601
http://dx.doi.org/10.1186/s12931-020-1307-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011474/
https://www.ncbi.nlm.nih.gov/pubmed/32041601
http://dx.doi.org/10.1186/s12931-020-1307-4

Ejemplares similares